The cheapest fix for health anxiety is the one without the trial
Health anxiety hits 1–2% of the population and clogs primary care. Individual CBT is proven; the group model that would actually scale has almost no randomized evidence behind it.
The call, up front. Severe health anxiety is chronic, costly, and common — 1–2% of Western populations, churning through medical resources for non-medical complaints. Individual CBT works but doesn’t scale. The group model scales but sits in an evidence vacuum. The gap is not a treatment; it is the randomized trial that would let payers fund the scalable one.
The gap
The market rewards what it can prove. Individual CBT has the evidence and none of the throughput; group CBT has the throughput and none of the evidence. The decision a health system actually faces is which model to fund — and right now the affordable one is unfundable.
Source: GAPTIQ engine — challenge definition; group-CBT randomized controlled trial (NCT02131883)
The bankable move is to generate the trial evidence for group CBT — the clinical work is done, the economic case isn't.
So what
Whoever runs the rigorous group-CBT trial doesn’t just publish a paper — they manufacture the reimbursement case for the lowest-cost-per-patient model in the category. The evidence is the product.
Source: Outcome of CBT for Patients With Severe Health Anxiety Treated in Group Only — A RCT, ClinicalTrials.gov. Surfaced by the GAPTIQ engine.